Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2.
Higa Y, Hiasa M, Tenshin H, Nakaue E, Tanaka M, Kim S, Nakagawa M, Shimizu S, Tanimoto K, Teramachi J, Harada T, Oda A, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Yamagami H, Endo I, Matsumoto T, Tanaka E, Abe M. Higa Y, et al. Among authors: teramachi j. Antioxidants (Basel). 2023 Jan 5;12(1):133. doi: 10.3390/antiox12010133. Antioxidants (Basel). 2023. PMID: 36670994 Free PMC article.
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.
Hiasa M, Teramachi J, Oda A, Amachi R, Harada T, Nakamura S, Miki H, Fujii S, Kagawa K, Watanabe K, Endo I, Kuroda Y, Yoneda T, Tsuji D, Nakao M, Tanaka E, Hamada K, Sano S, Itoh K, Matsumoto T, Abe M. Hiasa M, et al. Among authors: teramachi j. Leukemia. 2015 Jan;29(1):207-17. doi: 10.1038/leu.2014.147. Epub 2014 May 2. Leukemia. 2015. PMID: 24787487
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.
Amachi R, Hiasa M, Teramachi J, Harada T, Oda A, Nakamura S, Hanson D, Watanabe K, Fujii S, Miki H, Kagawa K, Iwasa M, Endo I, Kondo T, Yoshida S, Aihara KI, Kurahashi K, Kuroda Y, Horikawa H, Tanaka E, Matsumoto T, Abe M. Amachi R, et al. Among authors: teramachi j. Oncotarget. 2016 Oct 25;7(43):70447-70461. doi: 10.18632/oncotarget.11927. Oncotarget. 2016. PMID: 27626482 Free PMC article.
Expansion of Th1-like Vγ9Vδ2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.
Harada T, Miki H, Cui Q, Oda A, Amachi R, Teramachi J, Bat-Erdene A, Sogabe K, Iwasa M, Fujii S, Nakamura S, Kagawa K, Yoshida S, Endo I, Aihara K, Ozaki S, Matsumoto T, Abe M. Harada T, et al. Among authors: teramachi j. Leukemia. 2017 Jan;31(1):258-262. doi: 10.1038/leu.2016.273. Epub 2016 Oct 4. Leukemia. 2017. PMID: 27698446 No abstract available.
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A, Miki H, Oda A, Nakamura S, Teramachi J, Amachi R, Tenshin H, Hiasa M, Iwasa M, Harada T, Fujii S, Sogabe K, Kagawa K, Yoshida S, Endo I, Aihara K, Abe M. Bat-Erdene A, et al. Among authors: teramachi j. Oncotarget. 2016 Nov 29;7(48):79064-79075. doi: 10.18632/oncotarget.12594. Oncotarget. 2016. PMID: 27738323 Free PMC article.
Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, Tenshin H, Iwasa M, Fujii S, Kagawa K, Miki H, Kurahashi K, Yoshida S, Endo I, Haneji T, Matsumoto T, Abe M. Teramachi J, et al. Br J Haematol. 2018 Feb;180(4):581-585. doi: 10.1111/bjh.14388. Epub 2016 Oct 17. Br J Haematol. 2018. PMID: 27748523 Free article. No abstract available.
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, Watanabe K, Iwasa M, Harada T, Fujii S, Kagawa K, Sogabe K, Nakamura S, Miki H, Kurahashi K, Yoshida S, Aihara K, Endo I, Tanaka E, Matsumoto T, Abe M. Tenshin H, et al. Among authors: teramachi j. Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14. Blood Adv. 2017. PMID: 29296860 Free PMC article.
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S, Nakamura S, Oda A, Miki H, Tenshin H, Teramachi J, Hiasa M, Bat-Erdene A, Maeda Y, Oura M, Takahashi M, Iwasa M, Endo I, Yoshida S, Aihara KI, Kurahashi K, Harada T, Kagawa K, Nakao M, Sano S, Abe M. Fujii S, et al. Among authors: teramachi j. Br J Haematol. 2018 Jan;180(2):246-258. doi: 10.1111/bjh.15033. Br J Haematol. 2018. PMID: 29327347 Free article.
Effective impairment of myeloma cells and their progenitors by hyperthermia.
Miki H, Nakamura S, Oda A, Tenshin H, Teramachi J, Hiasa M, Bat-Erdene A, Maeda Y, Oura M, Takahashi M, Iwasa M, Harada T, Fujii S, Kurahashi K, Yoshida S, Kagawa K, Endo I, Aihara K, Ikuo M, Itoh K, Hayashi K, Nakamura M, Abe M. Miki H, et al. Among authors: teramachi j. Oncotarget. 2017 Dec 7;9(12):10307-10316. doi: 10.18632/oncotarget.23121. eCollection 2018 Feb 13. Oncotarget. 2017. PMID: 29535808 Free PMC article.
51 results